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inflexibly. We would argue that the SSRIs do have an important 
role to play in psychiatric practice, including that of child and 
adolescent psychiatry, and that clinicians should, as always, 
balance the benefits and risks for any particular patient and 
keep the interests of the patient paramount. Obtaining an 
expert opinion from a child and adolescent psychiatrist would 
be useful in situations where a practitioner is unsure.  We hope 
that the MCC will urgently reconsider the wording of this 
directive, in the interests of the many young patients who may 
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Rocephin – the thin end of the wedge 
To the Editor: I am sure I speak for many colleagues who have 
been cajoled, squeezed, begged and pressurised by medical 
aids, hospital administrators, pharmacists and representatives 
to stick to formularies to the point at which, backs against the 
wall, we say, ‘No more!’  The ‘thin edge of the wedge’ for me is 
the Rocephin issue.  
   I have grown up with Rocephin.  For me, rightly or wrongly, 
Rocephin is the drug that diminishes my anxiety, oh so slightly, 
over the safety of my patients; that may prevent meningitis 
secondary to sinus surgery; and that may stop a child’s 
otorrhoea when other drugs have failed and prevent him or her 
from developing mastoiditis.
   But despite evidence that many generics are inferior,1 the 
pressure is on me not to use Rocephin, but to prescribe a 
generic, for the vast saving of about R5 per dose.
   When will this pressure stop?  If I surrender on the Rocephin 
issue, what comes next? Are the medical aid administrators, 
the hospital managers and the pharmaceutical buyers willing 
to share the medical risk that I face on a daily basis?  Will 
they stand in the dock with me one day, and admit to using 
medications that are not proven to be equal in efficacy?
   We hear so much about ‘sharing risk’ nowadays. The best 
way those pressurising me to use ‘their’ not ‘my’ choice of 
drugs can share risk, is by sharing my risk.  What about, as 
a suggestion, paying all or part of my medical indemnity 
insurance?
   I’m not looking for handouts.  I’m not looking for perverse 
incentives.  I don’t even know, or care, whether the ‘local’ 
generic ceftriaxone is equivalent to Rocephin.  For a saving 
of only R5 a dose? I learn from one generic manufacturer that 
their local factory manufacturing quality is excellent, and then I 
hear that the drug I am interested in is allegedly manufactured 
in Turkey, shipped to Germany, and then to South Africa where 
it is distributed.
   For me there is a line I dare not cross, on the other side of 
which my autonomy stands for nothing.  Where I still have 
a choice, I must fight to maintain it, lest that thin edge of the 
wedge be pushed in further and further, until it becomes a 
thick edge, and then a wall.  ‘Rocephin’ for me is that issue, 
and I will not budge.  It is time we as a collective organisation 
of medical professionals stand up and say to those who would 
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Problematic childhood atopic eczema 
consensus document? 
To the Editor: The childhood atopic eczema consensus 
document published as part 2 of the June issue of the SAMJ1 is 
problematic and necessitates the following comments.
   A discussion of the controversy over the definition of atopic 
eczema is necessary, particularly in view of the recommen-
dations that pertain to allergy testing. Without this the rest of 
the article is open to misinterpretation. When dermatologists 
speak of atopic eczema they mean a clinical diagnosis. As 
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mentioned by the authors, the diagnosis of atopic eczema 
according to the World Allergy Organization’s Nomenclature 
Review Committee cannot be made without a positive 
immunoglobulin E (IgE) antibody or skin-prick test.2 
   While allergy specialists believe that specific IgE sensitisation 
(food and environment) is central to development of atopic 
eczema, the role of allergy in the pathogenesis of clinical 
atopic eczema is at best controversial. A systematic review 
of 65 studies,3 where children with clinical features of atopic 
eczema were tested for serum IgE antibodies or had a skin-
prick test, found a prevalence of 7 - 78% in population studies 
and 47 - 75% in hospital-based studies. This means that as few 
as 7% of clinical atopic eczema children could have positive 
allergy tests. Although dermatologists would diagnose all these 
children as having atopic eczema, allergologists would exclude 
those with negative IgE or skin-prick tests. Another important 
finding of this systematic review was that of the 8 studies that 
identified a link between atopy and atopic dermatitis severity, 
7 studies concluded that the number of skin-prick tests or IgE 
antibody specificities were significantly associated with atopic 
eczema severity.3 This would concur with current dermatology 
practice, to consider ‘allergy’ in severe (and non-responsive) 
disease.
   When it comes specifically to food allergy, the document 
mentions only one reference that quotes ‘up to 80% of infants 
with atopic eczema will have positive food allergy tests’, 
without mentioning other studies with lower prevalence 
figures. A comprehensive epidemiological study found that 
in infancy, ‘As atopic dermatitis severity increased so did the 
prevalence of IgE-mediated food allergy (Group 0, 40/346 vs. 
Group 1, 6/36 vs. Group 2, 8/35 vs. Group 3, 12/35 vs. Group 
4, 24/35).’4 This was a birth cohort from ‘atopic families’ where 
group 0 had no atopic eczema and groups 1 - 4 had increasing 
disease severity. Therefore the prevalence of food allergies in 
that study increased from 11.5% (in the no eczema group) to 
16.5%, 23%, 34% and 69% in those with more severe atopic 
eczema.4 
   As (clinical) atopic eczema is not severe in the majority of 
infants, the prevalence of food allergy would be expected to 
be much lower in most patients. In addition, the previously 
mentioned statement (‘up to 80% of infants with atopic eczema 
will have positive food allergy tests’) is not qualified by 
mentioning that at least in some patients the diagnosed food 
allergies do not correlate with the severity of atopic eczema, 
as evidenced by the variable response to exclusion diets. For 
example, in one study a diet that excluded eggs was found 
to improve atopic eczema in children who tested positive 
for egg allergy,5 but in another study this benefit was only 
limited to those aged between 3 and 6 months.6 In view of 
the above controversy it is worrying that the document goes 
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on to state that ‘testing for food allergy is an essential part of 
the management …’ This is indeed misleading and would not 
only have horrendous cost implications but also not improve 
the care of most of our patients. General practitioners and 
dermatologists treat the majority of ‘clinical’ atopic eczema 
patients who respond well to standard treatment. 
   What about the rest of the world?  An American study7 
concluded that ‘… at present, there is scant evidence that 
allergy is central to the development of atopic dermatitis, 
although it may be an aggravating factor in a few patients. 
Hence there is little rationale for the routine use of allergy 
testing … in the management of this disease.’ The most 
recent guidelines, the Canadian Atopic Eczema Guidelines,8 
which use a clinical definition of atopic eczema, state: ‘Some 
physicians send selected patients (i.e., those who fail to 
respond to standard therapy) for allergy testing to try to 
identify specific environmental or food allergies.’    In a 
questionnaire-based study9 investigators found that with 
effective topical treatment of atopic eczema ‘Parental concern 
of food allergy decreased significantly from 7.7 to 4.0 on a 10 
point scale (P < .001).’ The latter is a helpful study to bear in 
mind when dealing with parents who insist on allergy testing. 
   Finally, the take-home message for the management of 
clinical atopic eczema at any age should be to aim for adequate 
topical care, referring poor responders to or discussing such 
cases with dermatologists who have a wide armamentarium 
that includes in-hospital care, ultraviolet light and systemic 
treatment. It is only in a few, mainly younger patients with 
unresponsive disease, that allergy testing and exclusion diets 
may be helpful. There is no agreement between dermatologists 
and allergy specialists on the definition of atopic eczema, 
as evidenced by the latest guidelines.8 Interdisciplinary 
discussions and such an agreement would help to reduce 
confusion.
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   P C Potter, A I Manjra, R Weiss, P du Plessis, N Rabobee, 
N Ndlova, M Davies and E Weinberg (Members of the SA 
Childhood Working Group of the Allergy Society of South 
Africa) reply: We welcome the opportunity to respond to Dr 
Khumalo’s letter.  We emphasise that these are guidelines for 
paediatric eczema. Not all cases of eczema are ‘atopic’, and the 
term ‘intrinsic’ or ‘constitutional dermatitis’ was applied to the 
subgroup that has no IgE elevation. Those with IgE elevation 
are in the ‘atopic’ eczema group.  Eczema has always been 
understood as being atopic or non-atopic.
   The new nomenclature guidelines1 state that although atopy 
can be suggested by a family history, or certain physical 
features, e.g. Dennies lines, associated rhinitis or asthma, it can 
only be confirmed by the documentation of positive specific 
IgE tests to environmental allergens. Atopy is therefore defined 
as ‘… a personal or familial tendency to produce IgE antibodies 
in response to low dose of allergens, usually proteins and to 
develop typical symptoms such as asthma, rhinoconjunctivitis 
or eczema/dermatitis’.1  The name ‘atopic’ implies that the 
patient is sensitised to allergens that can result in exacerbation 
of symptoms and should therefore be avoided.  
   Some patients with eczema have significant food allergy. 
Several studies2 have proved that food allergens exacerbate 
symptoms in children with atopic dermatitis. Implications 
of distinguishing atopic from non-atopic eczema include 
prevention of adverse reactions to food, preventing asthma 
development, indications for probiotics, and the prevention of 
eczema flares. These interventions require specific confirmation 
of elevation specific IgE in children with eczema. In a large 
study3 of infants with eczema, asthma prevention of more than 
50% was possible in those children sensitive to house dust 
mites and grass pollen.
   Dr Khumalo addresses the question of prevalence of IgE 
sensitisation in patients with eczema, quoting studies of Flohr 
et al.4 The low rate of 7% that he quotes was derived from 
unvalidated questionnaire data from Kota Kinabala, Borneo, 
Malaysia, where the overall percentage of allergy present in 
the community was estimated to be only 4% in the non-atopic 
dermatitis group. 
   In June 2005 data were presented at the World Allergy 
Organization Congress in Munich from the EPAAC study 
(WAO-EAACI congress proceedings) on allergy prevalence 
in infants with eczema. In this study from Europe, Australia 
and South Africa, 60% of 2 184 infants aged 1 - 2 years with 
mild to moderate eczema (atopic dermatitis) had an elevated 
IgE. In the South African subgroup of 161 children, 47% were 
sensitised to egg, 28.4% to milk, 26.8% to peanut and 39.9% to 
house dust mites.  
   Dr Khumalo is incorrect in stating that testing for food 
allergy would have ‘horrendous cost implications’ as skin tests 
for the 5 common allergens can be performed for R75 in private 
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practice (and at less cost for state patients), less than the cost 
of a small tube of most topical corticosteroids. Our eczema 
guidelines recommend testing for 4 - 5 food allergens and 
possibly for house dust mites using skin tests. RAST tests are 
inexpensive if one restricts them to the 4 - 5 relevant allergens 
(egg, milk, peanut, soya, wheat, and house dust mites), based 
on a history of the patient’s diet and geographical location.
   The role of IgE Fce receptor, mast cell, basophil and T-cell 
responses in the pathogenesis of eczema is complex and in 
some cases depends on environmental exposure.  The role of 
IgE in non-atopic dermatitis, which mainly involves a TH-1 
response, is less clear.
   One cannot call all cases of this heterogeneous disease atopic 
dermatitis without even doing allergy diagnostic tests. In 
citing the paper by Flohr et al.4 Dr Khumalo did not refer to 
their conclusion, namely that ‘continued use of the term atopic 
dermatitis is problematic’.
   Dr Khumalo concurs that those eczema children who are 
‘poor responders’ have a chance of up to 69% of being allergic, 
but in his ‘take-home message’ suggests that they should 
receive hospital care, ultraviolet light and systemic treatment!  
This contradicts his previous statement, as the cost of such 
treatment would be very expensive, whereas exclusion diets 
are free. These recommendations should not be considered 
before food allergies have been excluded. Patients who do 
not respond to simple conventional topical treatments should 
receive a panel of inexpensive allergy skin tests or selected 
RAST testing. They would also benefit from an assessment by a 
practitioner with an interest in allergy.  
   Dr Khumalo is incorrect in asserting that there is ‘no 
agreement between dermatologists and allergy specialists 
on the definition of atopic eczema’ as dermatologists and 
allergists have embraced the new nomenclature worldwide. 
His statement reflects the sentiments of a few old-school 
practitioners who continue with the incorrect use of the term 
‘atopic dermatitis’ in eczema patients who have no evidence of 
atopy!  This should be called ‘non-atopic eczema’.
   Having recognised the importance of allergy in children 
with eczema it is likely that working relationships between 
dermatologists and allergy specialists will continue to 
strengthen. 
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Minimal access or minimal invasive 
surgery
To the Editor: In an excellent paper at the 2005 Congress of the 
South African Society of Obstetricians and Gynaecologists, Dr 
E Rosemann stated that ‘laparoscopy is the leading cause for 
legal action against gynaecologists in South Africa, and … it is 
a growing industry’.1 In my opinion, and also that of others,2 
a major reason is that laparoscopic surgery has been industry-
driven, with the consequence that major procedures have been 
performed without proper prior research or training. 
   A second reason is that the terms ‘minimal access’ and 
‘minimal invasive surgery’ are both used to indicate that an 
operation is associated with minimal trauma, and therefore 
minimal risk of complications and early discharge from 
hospital. This concept is wrong and misleading, since minimal 
access does not necessarily imply that minimal invasive 
surgery will be performed. The term minimal access surgery 
means that small incisions are used to gain access to the 
abdomen or pelvis, usually for diagnostic laparoscopy or 
laparoscopic surgery. This term can also be used for mini-
laparotomy. The term minimal invasive surgery means that 
a minor operative procedure has been performed inside the 
abdomen or pelvis, e.g. a partial salpingectomy for an early 
tubal pregnancy.
   However, minimal access (or minimal entrance) can also be 
used for maximal invasive surgery, e.g. radical hysterectomy 
and lymphadenectomy for cervical cancer. This requires 
a highly trained and skilled laparoscopic surgeon, or the 
operation will be fraught with danger.
   In conclusion, the terms minimal access and minimal 
invasive surgery are not synonymous.  This implies that even 
where a minimal access route of entrance to the abdomen 
or pelvis is used, the degree of invasion of the surgery to be 
performed will determine the degree of surgical expertise 
required.  The type of surgery should be based on the findings 
of well-designed prospective clinical trials.  In the absence of 
such trials, the safest and most beneficial approach should be 
used.  An example is early ovarian cancer, where the role of 
laparoscopy is undefined, and laparotomy is still the gold-
standard surgical procedure for diagnosis and staging.3  
J T Nel
Department of Obstetrics and Gynaecology
University of the Free State
Bloemfontein
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